|
|
| Product Name: | PQA-18 | | Synonyms: | PQA-18;2-Quinolinecarboxylic acid, 4,8-bis[(3-methyl-2-buten-1-yl)oxy]-, 3-methyl-2-buten-1-yl ester | | CAS: | 1604678-82-1 | | MF: | C25H31NO4 | | MW: | 409.52 | | EINECS: | | | Product Categories: | | | Mol File: | 1604678-82-1.mol |  |
| | PQA-18 Chemical Properties |
| Boiling point | 545.702±45.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.075±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 3.055±0.10(predicted) | | form | Solid | | color | Light yellow to yellow |
| | PQA-18 Usage And Synthesis |
| Uses | PQA-18 is a unique PAK2 inhibitor (IC50: 10 nM). PQA-18 has immunosuppressing effects. PQA-18 suppresses IL2, IL4, IL6, and TNFα. PQA-18 inhibits the population of a subset of regulatory T cells and the immunoglobulin (Ig) production against T cell-dependent antigens as well as alleviates dermatitis in mice[1]. | | in vivo | PQA-18 (0.5 mg/kg, i.p., three times a week) displays immunosuppressing activity in C57BL/6J mice immunized with NP-CGG, with inhibiting the population of a subset of regulatory T cells and the immunoglobulin (Ig) production against T cell-dependent antigens[1].
PQA-18 ointment (100 mg/mouse, contains 0.05%-0.1% PQA-18, three times a week, 17 weeks) improves dermatitis and IgE levels in Nc/Nga mice[1].
| Animal Model: | Male C57BL/6J mice (10 weeks old) immunized by intraperitoneal injection of 50 μg NP-CGG[1] | | Dosage: | 0.5 mg/kg | | Administration: | Intraperitoneal injection (i.p.); three times a week | | Result: | Suppressed the NP-specific responses (IgM, IgG1, and IgG3) in peripheral blood.
Significantly suppressed the number of Foxp3+CD4+CD25+ cells in spleens.
|
| | IC 50 | PAK2: 10 nM (IC50); IL-6; IL4; IL-2 | | References | [1] Ogura M, et al. Prenylated quinolinecarboxylic acid derivative suppresses immune response through inhibition of PAK2. Biochem Pharmacol. 2016 Apr 1;105:55-65. DOI:10.1016/j.bcp.2016.01.020 |
| | PQA-18 Preparation Products And Raw materials |
|